Immunic Presents New Clinical, Biomarker, and Preclinical Data for Vidofludimus Calcium in Four Poster Presentations at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic presented four posters of new clinical, biomarker, and preclinical data for vidofludimus calcium (IMU-838) at the joint ACTRIMS-ECTRIMS meeting in Toronto. Phase 2 CALLIPER open-label extension data showed durable disability-outcome trends with continued treatment, and post-hoc analyses using novel bidirectional endpoints showed patients 2.47x more likely to achieve confirmed disability improvement (p=0.037). Preclinical work suggested Nurr1-dependent neuroprotection beyond DHODH inhibition. Importantly, the CALLIPER primary endpoint (percent brain volume change) was not met -- these are exploratory and post-hoc findings.
Key figures
- Drug Name
- vidofludimus calcium (IMU-838)
- Phase Of Trial
- Phase 2 (CALLIPER); Phase 3 ENSURE ongoing
- Ole teae rate
- 44.4%
- Cdi odds ratio
- 2.47x (nominal p=0.037)
- Gpc odds ratio
- 1.5x (p=0.042)
- Ole participants
- 387
- Ebv trb reduction
- -0.65 matches (p=0.0004)
- Ensure topline timing
- by year-end 2026
- Ole discontinuation rate
- 6.5%
- Patients exposed cumulative
- 3500
- Callipor randomized patients
- 467
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.